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Aim: To describe spontaneously reported cases of erectile dysfunction (ED) in association with 
angiotensin II type I blockers (ARB) and other antihypertensive drugs.
Subjects and methods: All spontaneously reported cases of ED submitted to the Swedish 
Medical Products Agency (MPA) between 1990 and 2006, where at least one antihypertensive 
drug was the suspected agent, were scrutinized. Patient demographics, drug treatment and 
adverse reactions were recorded. Using the Bayesian Confidence Propagation Neural Network 
(BCPNN) method, the information component (IC) was calculated.
Results: Among a total of 225 reports of ED, 59 involved antihypertensive drugs including ARB 
(9 cases) as suspected agents. A positive IC value was found indicating that ED was reported more 
often in association with antihypertensive drugs classes, except for angiotensin-converting enzyme 
inhibitors, compared with all other drugs in the database. Positive dechallenge was reported in 43 
cases (72%).
Discussion: All classes of major antihypertensive drugs including ARB were implicated as 
suspected agents in cases of ED. Few risk factors were identified. The relatively high report-
ing of ED in association with ARB is in contrast with previous studies, suggesting that ARB 
have neither a positive nor any effect on ED. This discrepancy suggests that further studies are 
warrnted on this potential adverse reaction to ARB.
Keywords: adverse drug reaction, spontaneous reporting, antihypertensive drugs, angiotensin II 
type 1 receptor blockers, erectile dysfunction
Background
Erectile dysfunction (ED), ie, the consistent or recurrent inability of a man to attain 
and/or maintain penile erection sufficient for sexual activity,1 is a common disorder 
with a reported prevalence between 13% and 46% in the general population and with 
an exponential increase in occurrence from 60 years of age.2 Various medical, psy-
chological and lifestyle factors have been implicated in the pathogenesis. Diabetes, 
hypertension, hyperlipidemia, obesity, smoking, and lack of physical activity are 
established risk factors for ED.3
Drugs can have adverse effects on sexual function in several dimensions: central 
effects by sedation and loss of libido, central and peripheral effects by influencing 
neurotransmitters and receptors.4 Use of antihypertensive drugs has been associated 
with ED5 although the relationship has been disputed.6 Diuretics and adrenergic 
beta-antagonists (beta-antagonists) have been reported to have negative outcomes on 
various endpoints regarding sexual function. Calcium channel blockers (CCB) and 
angiotensin-converting enzyme (ACE) inhibitors have not been associated with major Drug, Healthcare and Patient Safety 2010:2 22
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negative impact on ED. It has also been suggested that angio-
tensin II type 1 receptor blockers (ARB) would affect sexual 
function less than other antihypertensive treatment.2,7 Some 
data even suggest that sexual function and ED may improve 
during treatment with ARB.8–10
In view of the fact that studies are lacking, limited infor-
mation is available from daily clinical practice, and ARBs 
may differ in this respect from other antihypertensive drugs, 
we wanted to study spontaneous reports of ED for different 
groups of antihypertensive drugs. In addition, we wanted to 
characterize cases of ED in terms of risk factors.
Methods
To study reports from clinical practice on ED during treat-
ment with antihypertensive drugs, we reviewed spontaneous 
reports in the Swedish adverse drug reaction (ADR) database 
(SWEDIS). The groups of antihypertensive drugs were iden-
tified according to their ATC code (Anatomic Therapeutic 
Chemical classification) as defined by the WHO Collabo-
rating Center for Drug Statistics Methodology. ATC C03A 
(thiazide diuretics), C07 AA and AB (beta-antagonists), 
C08 (CCB), C09A (ACE inhibitors), and C09C (ARB) 
were included. According to the Swedish Medical Products 
Agency’s (MPA) code of statutes, it is mandatory for health 
care professionals to report serious reactions, new and unex-
pected reactions and also those ADRs that seem to increase 
in frequency. For new drugs reporting of all adverse effects 
except those labeled as common in the Summary of Product 
Characteristics (SPC) is encouraged. An ADR is defined by 
the World Health Organization (WHO) as “a response to a 
drug which is noxious and unintended, and that occurs at 
doses normally used in humans for the prophylaxis, diagnosis, 
or therapy of disease or for the modification of physiological 
function”.
All cases of suspected ED associated with antihyperten-
sive drugs reported to SWEDIS during the period 1990 to 
2006 were identified and studied. In SWEDIS the following 
information can be obtained in addition to the suspected drug 
and the ADR: age, sex, concomitant medication, treatment 
dates, indication for treatment, concurrent diseases, dosage, 
and outcome of the reaction. Most reports also have a narra-
tive. Drugs can be listed as being suspected of having caused 
the reaction, as interacting with another prescribed drug, or as 
concomitant medication not related to the ADR. Each report 
can include more than one ADR and/or suspected drugs. The 
causality of the suspected ADR is classified using WHO cri-
teria (WHO Technical Report no 498, 1972). The reports are 
handled at regional centers situated at six university hospitals 
by an expert panel consisting of clinical pharmacologists and 
specially trained nurses and pharmacists. Thereafter the cases 
are re-evaluated at a national level by the MPA.
From the case reports the following information was 
collected when available: sex, age, reporting date, suspected 
drug(s), indication for treatment, duration of treatment, 
concomitant medication, outcome of the reaction, and type 
of reporter. Diabetes was identified when mentioned as 
concurrent disease in the narrative or when an antidiabetic 
drug was listed as concomitant.
Sales figures expressed as the number of defined daily 
doses (DDD) for Sweden for the corresponding period were 
obtained from the MPA. The DDD is the assumed average 
daily dose for a drug prescribed for its main indication in 
adults. The number of DDDs reflects the total sales, and not 
for men only. The number of sold DDDs was transposed to 
number of DDD years, one DDD year equalling the quantity 
used to treat one person with one DDD daily for one year.
Using the Bayesian Confidence Propagation Neural Net-
work (BCPNN) method, the strength of the statistical associa-
tion between a suspected drug and an ADR in a database can 
be calculated. This analysis provides a statistical indicator, the 
information component (IC), which in this study was used 
to assess the disproportionality between the observed and 
the expected number of reports, given the number of reports 
concerning the drug and the number of reports concerning the 
ADR in question.11,12 The IC is a logarithmic measure, and a 
positive IC-value with a positive (0) lower 95% confidence 
limit indicates a statistically significant disproportional-
ity. The BCPNN method has previously been described in 
detail11 and has been thoroughly tested and evaluated.13,14 
Moreover, the method has been found effective in identify-
ing early drug safety signals.11 Due to the tentative nature 
of the dataset, the method is used for hypothesis generation 
rather than for hypothesis testing. In this study, the BCPNN 
method was applied to SWEDIS reports concerning males 
between 1990 and 2006.
Results
Among a total of 23,176 adverse drug reactions reported in 
men during the 17-year study period, 225 (1%) reports of ED 
were identified. Of these, 59 (26%) occurred during treatment 
with antihypertensive drugs (Table 1). Most reports were 
found for CCBs whereas thiazide diuretics were the least 
reported. Concomitant antidiabetic drugs were mentioned in 4 
(7%) reports. The median age was under 60 years for all ATC-
groups, except for thiazide diuretics where the median age 
was 65. All cases were reported by physicians. Hypertension Drug, Healthcare and Patient Safety 2010:2 23
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was listed as the indication for treatment in 43 (73%) of the 
reports. Sixteen patients (27%) were treated with a combina-
tion of antihypertensive drugs from different ATC-classes. 
In one case a beta-antagonist as well as a thiazide diuretic 
was reported as suspected. In this report ED started when a 
thiazide diuretic had been added to metoprolol, and improved 
when metoprolol was withdrawn. This report is represented 
in both the beta-antagonist group and in the thiazide group. 
In the remaining reports only one antihypertensive drug was 
reported as a suspected drug. One report describes a patient 
that developed ED after generic substitution with metoprolol 
(not represented in Table 1).
In one case, treatment was changed from felodipine to 
enalapril, and in another report, treatment was changed from 
ramipril to losartan, in both cases the change of therapy had 
a beneficial effect on the ED. No concomitant medication 
was mentioned in 15 (25%) reports, whereas information 
on concomitant medication was missing or unknown in 9 
(15%). In the group with beta-antagonists one patient was 
treated concomitantly with tadalafil, a phosphodiesterase 
type 5 (PDE5) enzyme inhibitor, and in the ACE inhibitor 
group, one patient was treated with citalopram, a selective 
serotonin reuptake inhibitor, a drug known to be able to 
induce sexual dysfunction,15 both as concomitant medication 
(both represented in Table 1).
Sales figures and disproportionality  
of reporting (ic-values)
During the study period the sales figure expressed as million 
DDD years were highest for beta-antagonists, and lowest 
for ARBs (Table 2). However the reporting rate of ED per 
million DDD years was highest for ARBs. The first ARB in 
Table 1 Summary of 59 spontaneously reported cases of erectile dysfunction submitted to the Swedish Medical Products Agency between 
1990 and 2006 and where at least one antihypertensive drug was suspected to have caused the reaction
 
 
 
Total  
number of 
reports N 
Reports with  
concomitant  
antihypertensive  
medication N (%)
Age years  
median  
(range) 
Time to onset  
median  
(range) 
Positive  
dechallenge  
N (%) 
Indication  
hypertension  
N (%) 
Diabetes¹   
N (%) 
 
Beta blocking  
agents
12 2 (17%)2 55 years  
(31–77)
7 months  
(weeks–4 years)
7 (58%) 6 (50%) 0
calcium channel  
blockers
23 10 (43%)3 53 years  
(34–70)
Days  
(1 day–3 years)
20 (87%) 20 (87%) 2 (9%)
AcE inhibitors 11 0 58 years  
(39–63)
5 months  
(9 days–2 years)
9 (82%) 7 (64%) 2 (18%)
Angiotensin ii  
receptor antagonists
9 2 (22%)4 53 years  
(41–75)
2 weeks  
(1 week–10 months)
5 (56%) 6 (67%) 0
Thiazide  
diuretics
5  1 (20%)5  65 years  
(60–72)
1 month  
(1 day–14 months)
3 (60%)  4 (80%)  0 
1Diabetes mentioned in the narratives or use of antidiabetic medication was described in the report; 2One subject had a thiazide diuretic and 1 subject had an angiotensin ii 
receptor antagonists as concomitant medication; 3Two subjects had a thiazide diuretic, 4 subjects beta-antagonists, and 4 subjects AcE inhibitors as concomitant medications; 
4One subject had a thiazide diuretic and one subject a beta-antagonist as concomitant medications; 5One subjects had a beta-agonist as a concomitant medication.
Table 2 Observed and expected number of reports of ED and corresponding IC values with 95% confidence limits, sales and reports 
per million DDD-years
   Number of reports  
N (expected)
IC value  IC 95% confidence  
limits
Sales (million  
DDD-years)
Reports/million 
DDD-years
Beta-antagonists 12 (2.8) 1.9 1.0–2.6 7.5 1.6
calcium channel blockers 23 (4.0) 2.4 1.8–2.9 5.0 4.6
AcE inhibitors 11 (7.1) 0.6 −0.4–1.3 5.6 2.0
Angiotensin ii receptor  
antagonists
9 (2.1) 1.9 0.8–2.7 1.3 6.7
Thiazide diuretics 5 (0.4) 2.7 1.2–3.7 1.7 2.9
Notes: 1 DDD-year = 365 DDDs.
Abbreviations: IC, information component; DDD, defined daily doses.Drug, Healthcare and Patient Safety 2010:2 24
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Sweden was launched in 1994 and the first report on ED was 
submitted in 1997, three reports were sent in 1999 and one 
in each year 2000, 2001, 2002, 2003 and 2005, respectively. 
All anti-hypertensives except ACE inhibitors demonstrate 
statistically significant IC-values, indicating a higher number 
of reports for ED than expected for these drugs. The highest 
IC-values were observed for CCBs and thiazide diuretics 
(Table 2).
Discussion
ED was reported in 1% of all ADR-reports for male subjects 
during the study period. The different drug classes of anti-
hypertensive drugs, including ARB, were all represented in 
the reports. As the risk to develop ED increases with age, it 
is noteworthy that the patients described in the reports were 
quite young. However, the impact of cardiovascular disease 
is greater among younger men with a higher probability of 
ED.16 According to sales statistics for 2006 from the National 
Board of Health and Welfare 55 to 60% of male users of thia-
zide diuretics, beta-antagonists, CCB, and ACE inhibitors are 
over 65 years of age. For ARB 49% of the male users were 
older than 65 (Official Statistics in Sweden, 2007 http://www.
socialstyrelsen.se/Publicerat/2007/9789/2007-46-4.htm 
[in Swedish]). Surprisingly, a concomitant antidiabetic 
medication was reported in only 4 out of 59 reports (7%). 
This might reflect a reporting bias in terms of an increased 
willingness to report ED if other risk factors such as high 
age or diabetes are absent. A vast majority of the patients 
were treated for hypertension, and ED is a known marker 
for hypertension.6
ARB was launched in Sweden during the study period, 
but we found no consistent reporting pattern, described as 
the Weber effect,17 for suspected ARB induced ED. This is in 
accordance with a previous study where no consistent report-
ing pattern was found for the overall reporting rate for ARB.18 
ARB demonstrates the highest reporting rate of ED per mil-
lion DDD years in comparison with other antihypertensive 
drugs studied. This must however be interpreted in the light 
of the overall ADR-reporting rate which was also highest for 
this drug group (data not shown). There was a statistically 
significant IC-value for all groups of antihypertensive drugs, 
except ACE inhibitors, indicating a higher than expected 
reporting rate of ED for these drugs. This is an interesting 
finding in view of results from other studies suggesting a 
positive effect of ARB on ED. In a study by Llisterri and 
co-workers a group of uncontrolled hypertensive men with 
sexual dysfunction was studied. After 12 weeks of treatment 
with losartan the reported rate of ED decreased from 75% 
to 12%.9 The claim that ARB have a positive effect on ED 
can to a certain degree be supported by experimental data 
showing that the human penile cavernous muscle tone is 
partly balanced by angiotension II induced contraction,19 
and by the suggestion that the ARB valsartan reversed ED 
in diabetic rats.20
A number of limitations should be acknowledged when 
interpreting data from spontaneous reporting systems. Infor-
mation in the reports is often incomplete making it difficult 
or impossible to establish causal relationships between the 
reported event and the drug. Moreover, there is a substantial 
underreporting of adverse events and the reporting is not 
homogenous.21 The reporting rate is affected by numerous 
factors. The severity of the reaction, whether the reaction is 
a labeled ADR or not, and if the reaction is associated with a 
newly launched drug, has been identified as important factors 
for determining whether or not to report an ADR.22 In Sweden 
ED is listed in the SPC (http://www.fass.se [in Swedish]) for 
the majority of thiazide diuretics, beta-antagonists, CCB, and 
ACE inhibitors. With the exception for irbersartan (Aprovel®; 
Sanofi-Aventis), ED is not listed in the SPC for ARBs and 
this may affect the willingness to report suspected ED for 
ARBs in accordance to the rules for reporting in Sweden. 
Moreover, there is also a possibility that ARBs are prescribed 
selectively to men with a probability to develop ED. A further 
problem with spontaneous reporting is to distinguish ADRs 
from the symptoms and the natural history of underlying 
diseases. Moreover, increased reporting of ED in association 
with newer drugs may be due to the fact that sexual health has 
been better recognized as a consequence of the introduction of 
PDE5 enzyme inhibitor. When treatment is available asking 
about sexual functions is likely to increase.23
Conclusion
All classes of major antihypertensive drugs including ARB 
were implicated as suspected agents in spontaneously 
reported cases of ED to the Swedish pharmacovigilance 
system. Of all reports few risk factors such as high age and 
diabetes were identified.The relatively high reporting of ED 
in association with ARB is in contrast with previous studies 
suggesting that ARB have no or a positive effect on ED. This 
discrepancy suggests that further studies are warranted on 
this potential adverse reaction to ARB.
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